- Home
- Automated
- List of product information
- RIMONAL EYE DROPS 0.15% W/V [SIN17034P]
RIMONAL EYE DROPS 0.15% W/V [SIN17034P]
Active ingredients: RIMONAL EYE DROPS 0.15% W/V
Product Info
RIMONAL EYE DROPS 0.15% W/V
[SIN17034P]
Product information
Active Ingredient and Strength | BRIMONIDINE TARTRATE - 0.15% W/V |
Dosage Form | SOLUTION, STERILE |
Manufacturer and Country | WORLD MEDICINE İLAÇ SAN VE TIC. A.Ş. - TURKEY |
Registration Number | SIN17034P |
Licence Holder | GOLDPLUS UNIVERSAL PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | S01EA05 |
4.1 Therapeutic indications
RIMONAL is indicated for reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension.
4.2 Posology and method of administration
Posology/frequency and duration of administration:
The recommended dose of RIMONAL is one drop in the affected eyes three times daily in every approximately 8 hours. If more than one topical ophthalmic drug is used, drugs should be administered at least 5 minutes apart.
Method of administration:
It is administrated by instilling into eyes. As with the other eye drops, to reduce possible systemic absorption, it is recommended that the lachrymal sac at the medial canthus is compressed with finger tips for one minute after each drops.
Additional information about special populations:
Renal/Hepatic impairment:
RIMONAL has not been studied in patients with hepatic or renal impairment; caution should be used in treating such patients.
Paediatric population:
Safety and effectiveness in pediatric patients have not been established.
Geriatric population:
Generally, there is no difference for safety or efficacy in elderly and other adult patients.
4.3 Contraindications
RIMONAL is contraindicated in newborns and infants (under 2 years of age).
RIMONAL is contraindicated in patients who are hypersensitive to brimonidine tartrate or any of the other ingredients of its composition.
RIMONAL is contraindicated in patients receiving monoamine oxidase (MAO) treatment.
